Abbott launches trial to evaluate Xience in 2.25 vessel size
Abbott Vascular has begun SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm version of its Xience V everolimus-eluting coronary stent system.
The SPIRIT Small Vessel trial is designed to study 250 patients at approximately 50 centers in the U.S., the company said. The primary endpoint is a composite measure of cardiac death and MI and target lesion revascularization (repeat procedures on the treated vessel) at one year.
The 2.25 mm stent system would offer physicians an option for treating coronary artery disease in narrower vessels that is based on Xience V, according to the Abbott Park, Ill.-based company. The Xience V 2.25 mm stent system received CE Mark approval and was launched in various countries in Europe, Asia and Latin America in March.
The SPIRIT Small Vessel trial is designed to study 250 patients at approximately 50 centers in the U.S., the company said. The primary endpoint is a composite measure of cardiac death and MI and target lesion revascularization (repeat procedures on the treated vessel) at one year.
The 2.25 mm stent system would offer physicians an option for treating coronary artery disease in narrower vessels that is based on Xience V, according to the Abbott Park, Ill.-based company. The Xience V 2.25 mm stent system received CE Mark approval and was launched in various countries in Europe, Asia and Latin America in March.